POSB20 Health Technology Assessment (HTA) of BRAF/MEK Inhibitors in Non-Resectable Metastatic BRAFV600 Melanoma Patients
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.130
https://www.valueinhealthjournal.com/article/S1098-3015(21)01925-2/fulltext
Title :
POSB20 Health Technology Assessment (HTA) of BRAF/MEK Inhibitors in Non-Resectable Metastatic BRAFV600 Melanoma Patients
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)01925-2&doi=10.1016/j.jval.2021.11.130
First page :
Section Title :
Open access? :
No
Section Order :
10896